Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events

Journal of Immunology

Volumn 184, Issue 3, 2010, Pages 1436-1444

  Boulkroun, Sheerazed ^a   Guenin Macé, Laure ^a   Thoulouze, Maria Isabel ^a   Monot, Marc ^a   Merckx, Anaïs ^b,d   Langsley, Gordon ^b,d   Bismuth, Georges ^c,d   Di Bartolo, Vincenzo ^a   Demangel, Caroline ^a  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT COCHIN   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; CALCIUM; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; LACTONE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MYCOLACTONE; PROTEIN KINASE LCK; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BURULI ULCER; CALCIUM CELL LEVEL; CELL STRESS; CELLULAR IMMUNITY; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL LINE; LIPID RAFT; MOUSE; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; GENETICS; IMMUNOLOGY; INTRACELLULAR FLUID; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; TIME;

ANIMALS; BACTERIAL TOXINS; BURULI ULCER; CELLS, CULTURED; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR FLUID; JURKAT CELLS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MICE; MICE, INBRED C57BL; MYCOBACTERIUM ULCERANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TIME FACTORS;

EID: 77949318100     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902854     Document Type: Article

References (36)

1. Demangel, C., T. P. Stinear, and S. T. Cole. 2009. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat. Rev. Microbiol. 7: 50-60.
2. Wansbrough-Jones, M., and R. Phillips. 2006. Buruli ulcer: emerging from obscurity. Lancet 367: 1849-1858.
3. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, et al. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49: 3182-3186.
4. Huygen, K., O. Adjei, D. Affolabi, G. Bretzel, C. Demangel, B. Fleischer, R. C. Johnson, J. Pedrosa, D. M. Phanzu, R. O. Phillips, et al. 2009. Buruli ulcer disease: prospects for a vaccine. Med. Microbiol. Immunol. (Berl.) 198: 69-77.
5. Guenin-Macé, L., R. Siméone, and C. Demangel. 2009. Lipids of pathogenic Mycobacteria: contributions to virulence and host immune suppression. Transbound Emerg Dis 56: 255-268.
6. George, K. M., D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman, R. Lee, and P. L. Small. 1999. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857. (Pubitemid 129501127)
7. Guarner, J., J. Bartlett, E. A. Whitney, P. L. Raghunathan, Y. Stienstra, K. Asamoa, S. Etuaful, E. Klutse, E. Quarshie, T. S. van der Werf, et al. 2003. Histopathologic features of Mycobacterium ulcerans infection. Emerg. Infect. Dis. 9: 651-656.
8. George, K. M., L. Pascopella, D. M. Welty, and P. L. Small. 2000. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect. Immun. 68: 877-883.
9. Hong, H., C. Demangel, S. J. Pidot, P. F. Leadlay, and T. Stinear. 2008. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat. Prod. Rep. 25: 447-454.
10. Coutanceau, E., L. Marsollier, R. Brosch, E. Perret, P. Goossens, M. Tanguy, S. T. Cole, P. L. Small, and C. Demangel. 2005. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell. Microbiol. 7: 1187-1196.
11. Pahlevan, A. A., D. J. Wright, C. Andrews, K. M. George, P. L. Small, and B. M. Foxwell. 1999. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-κ B function. J. Immunol. 163: 3928-3935.
12. Torrado, E., S. Adusumilli, A. G. Fraga, P. L. Small, A. G. Castro, and J. Pedrosa. 2007. Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect. Immun. 75: 3979-3988.
13. Simmonds, R. E., F. V. Lali, T. Smallie, P. L. Small, and B. M. Foxwell. 2009. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J. Immunol. 182: 2194-2202.
14. Coutanceau, E., J. Decalf, A. Martino, A. Babon, N. Winter, S. T. Cole, M. L. Albert, and C. Demangel. 2007. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J. Exp. Med. 204: 1395-1403.
15. Phillips, R., F. S. Sarfo, L. Guenin-Macé, J. Decalf, M. Wansbrough-Jones, M. L. Albert, and C. Demangel. 2009. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J. Infect. Dis. 200: 1675-1684.
16. Gooding, T. M., A. S. Kemp, R. M. Robins-Browne, M. Smith, and P. D. Johnson. 2003. Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin. Infect. Dis. 36: 1076-1077.
17. Phillips, R., C. Horsfield, S. Kuijper, S. F. Sarfo, J. Obeng-Baah, S. Etuaful, B. Nyamekye, P. Awuah, K. M. Nyarko, F. Osei-Sarpong, et al. 2006. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin. Vaccine Immunol. 13: 253-257.
18. Prévot, G., E. Bourreau, H. Pascalis, R. Pradinaud, A. Tanghe, K. Huygen, and P. Launois. 2004. Differential production of systemic and intralesional γ interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect. Immun. 72: 958-965.
19. Westenbrink, B. D., Y. Stienstra, M. G. Huitema, W. A. Thompson, E. O. Klutse, E. O. Ampadu, H. M. Boezen, P. C. Limburg, and T. S. van der Werf. 2005. Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin. Diagn. Lab. Immunol. 12: 125-129.
20. Yeboah-Manu, D., E. Peduzzi, E. Mensah-Quainoo, A. Asante-Poku, D. Ofori- Adjei, G. Pluschke, and C. A. Daubenberger. 2006. Systemic suppression of interferon-γ responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J. Leukoc. Biol. 79: 1150-1156.
21. Schütte, D., A. Um-Boock, E. Mensah-Quainoo, P. Itin, P. Schmid, and G. Pluschke. 2007. Development of highly organized lymphoid structures in buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl. Trop. Dis. 1: e2.
22. Schütte, D., and G. Pluschke. 2009. Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin. Biol. Ther. 9: 187-200.
23. Sarfo, F. S., R. O. Phillips, E. Ampadu, F. Sarpong, E. Adentwe, and M. Wansbrough-Jones. 2009. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin. Vaccine Immunol. 16: 61-65.
24. Hong, H., E. Coutanceau, M. Leclerc, L. Caleechurn, P. F. Leadlay, and C. Demangel. 2008. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targetsmononuclear cells in peripheral blood and lymphoid organs.PLoS Negl. Trop. Dis. 2: e325.
25. Serfling, E., A. Avots, and M. Neumann. 1995. The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim. Biophys. Acta 1263: 181-200.
26. Beretta, L., A. C. Gingras, Y. V. Svitkin, M. N. Hall, and N. Sonenberg. 1996. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 15: 658-664. (Pubitemid 26044579)
27. Chung, J., C. J. Kuo, G. R. Crabtree, and J. Blenis. 1992. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69: 1227-1236.
28. Harding, H. P., Y. Zhang, H. Zeng, I. Novoa, P. D. Lu, M. Calfon, N. Sadri, C. Yun, B. Popko, R. Paules, et al. 2003. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 11: 619-633.
29. Acuto, O., V. Di Bartolo, and F. Michel. 2008. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat. Rev. Immunol. 8: 699-712.
30. D'Oro, U., M. S. Vacchio, A. M. Weissman, and J. D. Ashwell. 1997. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation. Immunity 7: 619-628. (Pubitemid 28156630)
31. Snyder, D. S., and P. L. Small. 2003. Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb. Pathog. 34: 91-101.
32. Feske, S. 2007. Calcium signalling in lymphocyte activation and disease. Nat. Rev. Immunol. 7: 690-702.
33. Faith, A., C. A. Akdis, M. Akdis, H. U. Simon, and K. Blaser. 1997. Defective TCR stimulation in anergized type 2 T helper cells correlates with abrogated p56 (lck) and ZAP-70 tyrosine kinase activities. J. Immunol. 159: 53-60. (Pubitemid 127493684)
34. Gajewski, T. F., D. Qian, P. Fields, and F. W. Fitch. 1994. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc. Natl. Acad. Sci. USA 91: 38-42.
35. Gauld, S. B., R. J. Benschop, K. T. Merrell, and J. C. Cambier. 2005. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 6: 1160-1167.
36. Lowell, C. A. 2004. Src-family kinases: rheostats of immune cell signaling. Mol. Immunol. 41: 631-643.